-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Worldwide, severe depression (MDD) is the leading cause of disability, which affects people of all ages.
suffer from depression, including MDD, continue to suffer from severe illness, which has a significant negative impact on physical function and all aspects of life.
antidepressants currently available are effective in many patients, they take four to six weeks to take effect, and about one-third of patients do not respond to the treatments currently available.
Spravato's active pharmaceutical ingredient is esketamine, a non-competitive and subtype of non-selective activity-dependent N-methyl-D-tiandysteine (NMDA) subject antagonist with a unique new mechanism of action that works differently from other drugs currently on the market for depression.
NMDA receptor is a subtype of ionized glutamate receptor, which play a key role in the plasticity of synapses and the exchange of information between neurons.
in depression, it is thought that blocking NMDA can improve brain plasticity and enhance synactal connections.
U.S., Spravato was approved in March 2019 for a combined oral antidepressant for the treatment of adult patients with refractic depression (TRD).
, the FDA has granted Spravato breakthrough drug eligibility to treat TRD patients and MDD patients with an imminent risk of suicide.
in the European Union, Spravato was approved in December 2019 for the treatment of adult patients with A combined selective 5-serotonin reuptake inhibitor (SSRI) or 5-serotonin and epinephrine reuptake inhibitor (SNRI).
, patients with depression are considered to have TRD if they do not respond to at least two different antidepressant medications during their current moderate to severe depressive episodes.
() Original source: SPRAVATO (Esketamine Nasal Spray) Authorised in Europe for the Rapids Down of Depressive Symptoms in a Psychiatric Emergency for Patients Majors with Majors With Depressive Disorder<!--/ewebeditor:page->
